Indications
Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Composition
- Active substance
- umeclidinium bromide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Incruse Ellipta (previously Incruse)
- Active substance
- umeclidinium bromide
- ATC code
- R03BB07
- Group
- Respiratory system
- Therapeutic area
- Pulmonary Disease, Chronic Obstructive
- Marketing authorisation holder
- GlaxoSmithKline Trading Services Limited
- Status
- Authorised
- EU authorisation